Femasys (FEMY) Q2 2025 earnings summary

Executive summary

• Achieved 84.8% year-over-year sales growth in Q2 2025, driven by FemaSeed and FemVue sales.

• Secured major regulatory milestones, including EU MDR approval for FemBloc and approvals for FemaSeed and FemVue in Australia and New Zealand.

• Expanded commercial presence in Europe with a $400,000 FemBloc order in Spain and new distribution partnerships.

• Raised $4.5 million in June 2025 through public offering and private placement to support operations.

• Formed a partnership with Carolinas Fertility Institute and appointed a new Chief Commercial Officer to drive growth.

Financial highlights

• Q2 2025 sales: $409,268, up 84.8% year-over-year; six-month sales: $750,532, up 52.4% year-over-year.

• Net loss for Q2 2025: $4,585,922; six-month net loss: $10,482,761, up from $8,284,084 in 2024.

• Operating expenses for six months: $9.8 million, up 18.3% year-over-year, mainly due to increased R&D and sales/marketing costs.

• Cash and cash equivalents as of June 30, 2025: $3.2 million; accumulated deficit: $137.7 million.

• Net loss per share for Q2 2025: $(0.16); weighted average shares outstanding: 28,880,704.

Outlook and guidance

• Current cash and anticipated revenues expected to fund operations into early Q4 2025; additional financing required for ongoing operations and product development.

• Ongoing pivotal trial enrollment for FemBloc in the U.S. and plans to seek further country approvals in Europe.

• Continued investments planned in commercialization, clinical trials, and R&D for FemBloc and other products.

• Substantial doubt exists about ability to continue as a going concern without new funding.